Noticias y Actividades de Imbria Pharmaceuticals

Fusión, adquisición y financiación con participación de Imbria Pharmaceuticals.

• Imbria Pharmaceuticals acaba de anunciar una recaudación de fondos de 58 millones de dólares. (publicado el 10 de abril de 2025).

Ver el organigrama con sus 11 ejecutivos principales

Biografías más buscadas en Imbria Pharmaceuticals

• Alvin Shih, Chief Executive Officer
• Charles Dunn, Director
• James Januzzi, Director

Recientes movimientos de ejecutivos en Imbria Pharmaceuticals

• Alvin Shih que ha sido Executive Chairman of the Board, pasa a ser Chief Executive Officer  (noticia publicada el 10 de abril de 2025).

Crear su alerta
para seguir los movimientos de los ejecutivos en Imbria Pharmaceuticals.

Imbria Pharmaceuticals tiene 1.831 competidores entre los que se incluyen Pfizer (Estados Unidos), Sanofi (Francia) y Eli Lilly (Estados Unidos).

Popular M&A news in Farmacia

• Chimerix and Chimerix have merged  (publicado el 22 de abril de 2025)..
• Imbria Pharmaceuticals acaba de anunciar una recaudación de fondos de 58 millones de dólares. (publicado el 10 de abril de 2025).
• Clario ha NRx Pharmaceuticals adquirido (publicado el 18 de marzo de 2025).

Otros contactos sugeridos en el sector Farmacia

• Estelle Vester-Blokland - Senior Vice President, Medical and Head, International Markets en Bristol-Myers Squibb
• Kristin Berkinsky - Chief Human Resources Officer en Adare Pharmaceuticals
• Seth Harrison - Chairman and Director en Braeburn Pharmaceuticals

Saber más sobre el sector Farmacia

Últimos comunicados de prensa de Imbria Pharmaceuticals

• Imbria Pharmaceuticals Raises $57.5M Series B Financing Round and Appoints Alvin Shih, MD as CEO - Press Releases - Media Center - Imbria
• Imbria Pharmaceuticals Raises $57.5M Series B Financing Round and Appoints Alvin Shih, MD as CEO - Press Releases - Media Center - Imbria
• Imbria Presents Positive Clinical Data from Phase 2 IMPROVE-DiCE Trial of Ninerafaxstat in Patients with Cardiometabolic HFpEF at ACC.25 - Press Releases - Media Center - Imbria
• Imbria Presents Positive Clinical Data from Phase 2 IMPROVE-DiCE Trial of Ninerafaxstat in Patients with Cardiometabolic HFpEF at ACC.25 - Press Releases - Media Center - Imbria
• Imbria Pharmaceuticals to Present Results from Phase 2 IMPROVE-DiCE Trial of Ninerafaxstat in Patients with Cardiometabolic HFpEF at the American College of Cardiology Annual Scientific Session & Expo (ACC.25) - Press Releases - Media Center - Imbria
• Imbria Pharmaceuticals to Present Results from Phase 2 IMPROVE-DiCE Trial of Ninerafaxstat in Patients with Cardiometabolic HFpEF at the American College of Cardiology Annual Scientific Session & Expo (ACC.25) - Press Releases - Media Center - Imbria
• Imbria to Present Results from Phase 2 IMPROVE-ISCHEMIA Trial of Ninerafaxstat in Patients with Angina and Chronic Coronary Syndrome at the European Society of Cardiology Congress 2024 - Press Releases - Media Center - Imbria
• Imbria to Present Results from Phase 2 IMPROVE-ISCHEMIA Trial of Ninerafaxstat in Patients with Angina and Chronic Coronary Syndrome at the European Society of Cardiology Congress 2024 - Press Releases - Media Center - Imbria
• Press Releases - Media Center - Imbria
• Positive Results for Patients with Non-obstructive Hypertrophic Cardiomyopathy Treated with Ninerafaxstat in the Phase 2 IMPROVE-HCM Trial Presented During a Late-Breaking Clinical Trial Session at ACC.24 - Press Releases - Media Center - Imbria
• View more press releases Close

Redes sociales sobre Imbria Pharmaceuticals

• Imbria Pharmaceuticals en Wikipedia, Google News y Yahoo Finance
• Imbria Pharmaceuticals en LinkedIn, Twitter y YouTube